Drug class in one race
Nrf2 pathway (fumaric acid ester) drugs for Multiple Sclerosis
4 tracked Nrf2 pathway (fumaric acid ester) drugs in the Multiple Sclerosis race. The class explanation lives on the Nrf2 pathway (fumaric acid ester) page; the full indication pipeline across every mechanism is on the Multiple Sclerosis page.
4 approved / phase 4
Head-to-head evidence: Bafiertam vs DRF · Bafiertam vs Dimethyl fumarate (Tecfidera) · Bafiertam vs Diroximel fumarate · Dimethyl fumarate (Tecfidera) vs DRF · Diroximel fumarate vs DRF · Dimethyl fumarate (Tecfidera) vs Diroximel fumarate